Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Ultraviolet radiation, both UVA and UVB, influences the composition of the skin microbiome.

Burns EM, Ahmed H, Isedeh PN, Kohli I, Van Der Pol W, Shaheen A, Muzaffar AF, Al-Sadek C, Foy TM, Abdelgawwad MS, Huda S, Lim HW, Hamzavi I, Bae S, Morrow CD, Elmets CA, Yusuf N.

Exp Dermatol. 2019 Feb;28(2):136-141. doi: 10.1111/exd.13854. Epub 2019 Jan 14.

PMID:
30506967
2.

Quality control within the multicentre perfusion CT study of primary colorectal cancer (PROSPeCT): results of an iodine density phantom study.

Lewis M, Goh V, Beggs S, Bridges A, Clewer P, Davis A, Foy T, Fuller K, George J, Higginson A, Honey I, Iball G, Mutch S, Neil S, Rivett C, Slater A, Sutton D, Weir N, Wayte S; PROSPeCT Investigators.

Eur Radiol. 2014 Sep;24(9):2309-18. doi: 10.1007/s00330-014-3258-y. Epub 2014 Jul 8.

PMID:
25001085
3.

Relationship of occupational therapy inpatient rehabilitation interventions and patient characteristics to outcomes following spinal cord injury: the SCIRehab project.

Ozelie R, Gassaway J, Buchman E, Thimmaiah D, Heisler L, Cantoni K, Foy T, Hsieh CH, Smout RJ, Kreider SE, Whiteneck G.

J Spinal Cord Med. 2012 Nov;35(6):527-46. doi: 10.1179/2045772312Y.0000000062.

4.

A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation.

Scalley-Kim ML, Hess BW, Kelly RL, Krostag AR, Lustig KH, Marken JS, Ovendale PJ, Posey AR, Smolak PJ, Taylor JD, Wood CL, Bienvenue DL, Probst P, Salmon RA, Allison DS, Foy TM, Raport CJ.

PLoS One. 2012;7(8):e43332. doi: 10.1371/journal.pone.0043332. Epub 2012 Aug 17.

5.

The use of clinical broadband UV radiometers for optical radiation hazard measurements.

Foy T.

J Radiol Prot. 2011 Dec;31(4):453-65. doi: 10.1088/0952-4746/31/4/005. Epub 2011 Nov 17.

PMID:
22090154
6.

The SCIRehab project: treatment time spent in SCI rehabilitation. Occupational therapy treatment time during inpatient spinal cord injury rehabilitation.

Foy T, Perritt G, Thimmaiah D, Heisler L, Offutt JL, Cantoni K, Hseih CH, Gassaway J, Ozelie R, Backus D.

J Spinal Cord Med. 2011;34(2):162-75.

7.

Panayiotopoulos syndrome: a debate.

Appleton RE, Tedman B, Preston T, Foy T.

Epileptic Disord. 2010 Mar;12(1):91; author reply 91-2. No abstract available.

8.

A novel assessment of an evidence-based practice course using an authentic assignment.

Dory V, Gagnon R, De Foy T, Duyver C, Leconte S.

Med Teach. 2010;32(2):e65-70. doi: 10.3109/01421590903199718.

PMID:
20163218
9.

SCIRehab Project series: the occupational therapy taxonomy.

Ozelie R, Sipple C, Foy T, Cantoni K, Kellogg K, Lookingbill J, Backus D, Gassaway J.

J Spinal Cord Med. 2009;32(3):283-97.

10.

Growth characteristics of children with ectodermal dysplasia syndromes.

Motil KJ, Fete TJ, Fraley JK, Schultz RJ, Foy TM, Ochs U, Sybert VP.

Pediatrics. 2005 Aug;116(2):e229-34.

PMID:
16061575
11.

Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.

Retter MW, Johnson JC, Peckham DW, Bannink JE, Bangur CS, Dresser K, Cai F, Foy TM, Fanger NA, Fanger GR, Woda B, Rock KL.

Cancer Res. 2005 Jul 15;65(14):6425-34.

12.

Bioluminescent bacteria as indicators of chemical contamination of coastal waters.

Frischer ME, Danforth JM, Foy TF, Juraske R.

J Environ Qual. 2005 Jul 5;34(4):1328-36. Print 2005 Jul-Aug.

PMID:
15998855
13.

Rice-induced enterocolitis in an infant: TH1/TH2 cellular hypersensitivity and absent IgE reactivity.

Gray HC, Foy TM, Becker BA, Knutsen AP.

Ann Allergy Asthma Immunol. 2004 Dec;93(6):601-5.

PMID:
15609772
14.

A novel method for increasing the expression level of recombinant proteins.

Wang A, Clapper J, Guderian JA, Foy TM, Fanger GR, Retter MW, Skeiky YA.

Protein Expr Purif. 2003 Jul;30(1):124-33.

PMID:
12821330
15.

Designing HER2 vaccines.

Foy TM, Fanger GR, Hand S, Gerard C, Bruck C, Cheever MA.

Semin Oncol. 2002 Jun;29(3 Suppl 11):53-61. Review.

PMID:
12138398
16.

Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor.

Foy TM, Bannink J, Sutherland RA, McNeill PD, Moulton GG, Smith J, Cheever MA, Grabstein K.

Vaccine. 2001 Mar 21;19(17-19):2598-606.

PMID:
11257398
17.

Murine B1 B cells require IL-5 for optimal T cell-dependent activation.

Erickson LD, Foy TM, Waldschmidt TJ.

J Immunol. 2001 Feb 1;166(3):1531-9.

18.

Blockade of CD40-CD154 interferes with human T cell engraftment in scid mice.

Foy TM, McIlraith M, Masters SR, Dunn JJ, Rossini AA, Shultz LD, Hesselton RA, Wagar EJ, Lipsky PE, Noelle RJ, Greiner DL.

Cell Transplant. 1998 Jan-Feb;7(1):25-35.

PMID:
9489760
19.

Asymptomatic uveitis in young people with inflammatory bowel disease.

Rychwalski PJ, Cruz OA, Alanis-Lambreton G, Foy TM, Kane RE.

J AAPOS. 1997 Jun;1(2):111-4.

PMID:
10875088
20.

CD40 and its ligand in autoimmunity.

Noelle RJ, Mackey M, Foy T, Buhlmann J, Burns C.

Ann N Y Acad Sci. 1997 Apr 5;815:384-91. Review. No abstract available.

PMID:
9186684
21.

Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice.

Resetkova E, Kawai K, Enomoto T, Arreaza G, Togun R, Foy TM, Noelle RJ, Volpé R.

Thyroid. 1996 Aug;6(4):267-73.

PMID:
8875745
22.

Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice.

Green KA, Crassi KM, Laman JD, Schoneveld A, Strawbridge RR, Foy TM, Noelle RJ, Green WR.

J Virol. 1996 Apr;70(4):2569-75.

23.

CD40 and its ligand.

Clark LB, Foy TM, Noelle RJ.

Adv Immunol. 1996;63:43-78. Review. No abstract available.

PMID:
8787629
24.

Immune regulation by CD40 and its ligand GP39.

Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ.

Annu Rev Immunol. 1996;14:591-617. Review.

PMID:
8717526
25.

An essential role for gp39, the ligand for CD40, in thymic selection.

Foy TM, Page DM, Waldschmidt TJ, Schoneveld A, Laman JD, Masters SR, Tygrett L, Ledbetter JA, Aruffo A, Claassen E, Xu JC, Flavell RA, Oehen S, Hedrick SM, Noelle RJ.

J Exp Med. 1995 Nov 1;182(5):1377-88.

26.
27.

In the absence of a CD40 signal, B cells are tolerogenic.

Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, Xu JC, Shultz LD, Roopesian D, Flavell RA, et al.

Immunity. 1995 Jun;2(6):645-53.

28.

Chronic pancreatitis and obstructive jaundice from a round-cell tumor involving the pancreas.

Kane RE, Profumo RJ, Foy TM, O'Connor DM, Steigman CK, Burton FR.

J Pediatr Gastroenterol Nutr. 1995 Feb;20(2):229-32. No abstract available.

PMID:
7714691
29.

The expansive role of CD40 and its ligand, gp39, in immunity.

Foy TM, Durie FH, Noelle RJ.

Semin Immunol. 1994 Oct;6(5):259-66. Review.

PMID:
7532456
30.

Hyper IgM syndrome: two mutations distinguish HIM.

Foy TM, Masters SR, Noelle RJ.

J Clin Invest. 1994 Oct;94(4):1349-50. Review. No abstract available.

31.

The role of CD40 in the regulation of humoral and cell-mediated immunity.

Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ.

Immunol Today. 1994 Sep;15(9):406-11. Review.

PMID:
7524518
32.

Mice deficient for the CD40 ligand.

Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Flavell RA.

Immunity. 1994 Aug;1(5):423-31. Erratum in: Immunity 1994 Oct;1(7):following 613.

PMID:
7882172
33.

gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.

Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ.

J Exp Med. 1994 Jul 1;180(1):157-63.

34.

Colonic ulcers and lower GI bleeding due to disseminated aspergillosis.

Foy TM, Hawkins EP, Peters KR, Shearer WT, Ferry GD.

J Pediatr Gastroenterol Nutr. 1994 Apr;18(3):399-403. Review. No abstract available.

PMID:
8057229
35.

The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease.

Durie FH, Foy TM, Noelle RJ.

Res Immunol. 1994 Mar-Apr;145(3):200-5; discussion 244-9. Review. No abstract available.

PMID:
7527576
36.

Severe immobilization-induced hypercalcemia in a child after liver transplantation successfully treated with pamidronate.

Profumo RJ, Reese JC, Foy TM, Garibaldi LR, Kane RE.

Transplantation. 1994 Jan;57(2):301-3. No abstract available.

PMID:
8310527
37.

In vivo gp39-CD40 interactions occur in the non-follicular compartments of the spleen and are essential for thymus dependent antibody responses and germinal center formation.

van den Eertwegh AJ, Van Meurs M, Foy TM, Noelle RJ, Boersma WJ, Claassen E.

Adv Exp Med Biol. 1994;355:75-80. No abstract available.

PMID:
7535976
38.

Switching capacity of Fc epsilon RII-positive and -negative murine B cells.

Foy TM, Waldschmidt TJ.

Eur J Immunol. 1993 Dec;23(12):3208-16.

PMID:
7903073
40.

Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.

Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ.

Science. 1993 Sep 3;261(5126):1328-30.

PMID:
7689748
41.

Colonic acetate in the circulating acetate pool of the infant pig.

Freeman K, Foy T, Feste AS, Reeds PJ, Lifschitz CH.

Pediatr Res. 1993 Sep;34(3):318-22.

PMID:
8134174
42.
43.

Ontogeny and distribution of the murine B cell Fc gamma RII.

Foy TM, Lynch RG, Waldschmidt TJ.

J Immunol. 1992 Sep 1;149(5):1516-23.

PMID:
1387140
44.

B-cell subsets defined by the Fc epsilon R.

Waldschmidt T, Snapp K, Foy T, Tygrett L, Carpenter C.

Ann N Y Acad Sci. 1992 May 4;651:84-98. Review.

PMID:
1376093
45.

Ehrlichia canis infection in a child.

Barton LL, Foy TM.

Pediatrics. 1989 Sep;84(3):580-2. No abstract available.

PMID:
2771561
46.
47.

Isoproterenol and aminophylline reduce lung capillary filtration during high permeability.

Foy T, Marion J, Brigham KL, Harris TR.

J Appl Physiol Respir Environ Exerc Physiol. 1979 Jan;46(1):146-51.

PMID:
110756

Supplemental Content

Support Center